Elecsys® β-Amyloid(1-42) CSF

ElectroChemiLuminescence Immunoassay (ECLIA) for the in vitro quantitative determination of β-Amyloid(1-42) in human Cerebrospinal Fluid (CSF)

Elecsys® β-Amyloid(1-42) CSF

ElectroChemiLuminescence Immunoassay (ECLIA) for the in vitro quantitative determination of β-Amyloid(1-42) in human Cerebrospinal Fluid (CSF)

β-Amyloid (1-42) peptide deposition in the brain is one of the two hallmarks of Alzheimer’s Disease (AD), besides neurofibrillary tangles. Pathological changes in the β-Amyloid metabolism are the earliest alterations during AD development. These changes are reflected by the decrease in the CSF concentrations of β-Amyloid (1-42) as well as by the increase in the brain uptake of the specific tracers on the β-Amyloid PET.1

Elecsys β Amyloid (1 42) CSF (Abeta42) is an in vitro diagnostic immunoassay intended for the quantitative determination of the β amyloid (1 42) protein concentration in human cerebrospinal fluid (CSF).

 

Platform availability

MODULAR ANALYTICS E170, cobas e 601, cobas e 602

Elecsys® β-Amyloid(1-42) CSF

Elecsys® β-Amyloid(1-42) CSF

  • Systems

    cobas e 601 / cobas e 602 modules, MODULAR ANALYTICS E170

  • Testing Time

    18 minutes

  • Test principle

    Sandwich principle

  • Calibration

    2-point

  • Traceability

    LC-MS/MS

  • Sample material

    Human Cerebrospinal Fluid (CSF)

  • Sample volume

    50 μL

  • LoB (Limit of Blank)

    60 pg/mL

  • LoD (Limit of Detection)

    120 pg/mL

  • LoQ (Limit of Quantitation)

    200 pg/mL

  • Measuring range

    200-1700 pg/mL (defined by the Limit of Quantitation and the maximum of the master curve) 

    Values below the Limit of Quantitation are reported as < 200 pg/mL

    Values above the measuring range are reported as  > 1,700 pg/mL

  • Intermediate precision

    E170, cobas e 601, cobas e 602: 1.5% -4.0% (7.36-38.14 pg/mL)

References

 

  1. Lewczuk, P. et al. (2015). Advances in Medical Sciences 60, 76-82